Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Livermore

Showing results (51-60 of 269) with videos related to

Pageof 27
Sort By:
Haematologica|December 11, 2013
The role of antibiotic stewardship in limiting antibacterial resistance among hematology patientsInge C Gyssens, Winfried V Kern, David M Livermore, et al.
International Journal of Antimicrobial Agents|February 1, 2011
Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellaeDavid M Livermore, Shazad Mushtaq, Tue Nguyen, et al.
Antimicrobial Agents and Chemotherapy|November 11, 2015
Interactions of OP0595, a Novel Triple-Action Diazabicyclooctane, with β-Lactams against OP0595-Resistant Enterobacteriaceae MutantsDavid M Livermore, Marina Warner, Shazad Mushtaq, et al.
International Journal of Antimicrobial Agents|May 12, 2009
Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolatesDavid M Livermore, Shazad Mushtaq, Yigong Ge, et al.
The Journal of Antimicrobial Chemotherapy|January 24, 2009
Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococciDavid M Livermore, Shazad Mushtaq, Marina Warner, et al.
The Journal of Antimicrobial Chemotherapy|May 21, 2010
Proposed disc zone breakpoints for doripenem for use with the BSAC disc susceptibility testing methodRussell Hope, Teresa Pllana, Marina Warner, et al.
The Journal of Antimicrobial Chemotherapy|March 24, 2017
WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamasesShazad Mushtaq, Anna Vickers, Neil Woodford, et al.
The Journal of Antimicrobial Chemotherapy|November 22, 2013
Comparative in vitro activity of sulfametrole/trimethoprim and sulfamethoxazole/trimethoprim and other agents against multiresistant Gram-negative bacteriaDavid M Livermore, Shazad Mushtaq, Marina Warner, et al.
The Journal of Antimicrobial Chemotherapy|August 28, 2015
Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamasesDavid M Livermore, Shazad Mushtaq, Marina Warner, et al.
The Lancet. Infectious Diseases|March 5, 2011
Balkan NDM-1: escape or transplant?David M Livermore, Timothy R Walsh, Mark Toleman, et al.
Pageof 27

Showing results (51-60 of 269) with videos related to

Sort By:
Pageof 27
Haematologica|December 11, 2013
The role of antibiotic stewardship in limiting antibacterial resistance among hematology patientsInge C Gyssens, Winfried V Kern, David M Livermore, et al.
International Journal of Antimicrobial Agents|February 1, 2011
Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellaeDavid M Livermore, Shazad Mushtaq, Tue Nguyen, et al.
Antimicrobial Agents and Chemotherapy|November 11, 2015
Interactions of OP0595, a Novel Triple-Action Diazabicyclooctane, with β-Lactams against OP0595-Resistant Enterobacteriaceae MutantsDavid M Livermore, Marina Warner, Shazad Mushtaq, et al.
International Journal of Antimicrobial Agents|May 12, 2009
Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolatesDavid M Livermore, Shazad Mushtaq, Yigong Ge, et al.
The Journal of Antimicrobial Chemotherapy|January 24, 2009
Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococciDavid M Livermore, Shazad Mushtaq, Marina Warner, et al.
The Journal of Antimicrobial Chemotherapy|May 21, 2010
Proposed disc zone breakpoints for doripenem for use with the BSAC disc susceptibility testing methodRussell Hope, Teresa Pllana, Marina Warner, et al.
The Journal of Antimicrobial Chemotherapy|March 24, 2017
WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamasesShazad Mushtaq, Anna Vickers, Neil Woodford, et al.
The Journal of Antimicrobial Chemotherapy|November 22, 2013
Comparative in vitro activity of sulfametrole/trimethoprim and sulfamethoxazole/trimethoprim and other agents against multiresistant Gram-negative bacteriaDavid M Livermore, Shazad Mushtaq, Marina Warner, et al.
The Journal of Antimicrobial Chemotherapy|August 28, 2015
Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamasesDavid M Livermore, Shazad Mushtaq, Marina Warner, et al.
The Lancet. Infectious Diseases|March 5, 2011
Balkan NDM-1: escape or transplant?David M Livermore, Timothy R Walsh, Mark Toleman, et al.
Pageof 27